fluoxetine has been researched along with Brain Neoplasms in 13 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although temozolomide (TMZ) is the most effective chemotherapy agent for glioma, chemotherapy resistance has limited its clinical use." | 7.83 | Fluoxetine synergizes with temozolomide to induce the CHOP-dependent endoplasmic reticulum stress-related apoptosis pathway in glioma cells. ( Chen, MH; Chen, W; Ma, J; Sun, LL; Wang, DC; Wang, FZ; Wang, H; Wang, XD; Yang, YR, 2016) |
| "We studied the effect of fluoxetine, an SSRI, on the development of brain metastatic breast cancer using MDA-MB-231BR cells in a mouse model." | 7.80 | Fluoxetine modulates breast cancer metastasis to the brain in a murine model. ( Amico-Ruvio, SA; Brown, EB; Dickerson, IM; Kelly, EA; Majewska, AK; Shapovalov, Y; Sipe, GO; Spielman, SC; Zettel, M, 2014) |
| "In C6 glioma cells, we studied acute administration of SSRI antidepressants - fluoxetine, sertraline and citalopram." | 7.78 | Effect of fluoxetine and adenosine receptor NECA agonist on G alpha q/11 protein of C6 glioma cells. ( Kováru, F; Kovárů, H; Lisá, V, 2012) |
| "We studied the effect of acute administration of fluoxetine or NECA agonist of adenosine receptor (GPCR) on C6 glioma cells and natural killer (NK) cell line, innate immunity." | 7.77 | Effect of fluoxetine or adenosine receptor NECA agonist on G-proteins of C6 glioma cells or NK immunocytes. ( Fiserová, A; Kovaru, F; Kovárů, H; Lisá, V; Ondráčkova, P, 2011) |
| " However, vital safety and efficacy issues related to combined therapy with temozolomide, the first-line cytostatic in patients diagnosed with glioblastoma multiforme, and antidepressant drugs have yet to be addressed." | 3.85 | Antidepressant drugs can modify cytotoxic action of temozolomide. ( Bielecka, AM; Obuchowicz, E, 2017) |
| "Although temozolomide (TMZ) is the most effective chemotherapy agent for glioma, chemotherapy resistance has limited its clinical use." | 3.83 | Fluoxetine synergizes with temozolomide to induce the CHOP-dependent endoplasmic reticulum stress-related apoptosis pathway in glioma cells. ( Chen, MH; Chen, W; Ma, J; Sun, LL; Wang, DC; Wang, FZ; Wang, H; Wang, XD; Yang, YR, 2016) |
| "We studied the effect of fluoxetine, an SSRI, on the development of brain metastatic breast cancer using MDA-MB-231BR cells in a mouse model." | 3.80 | Fluoxetine modulates breast cancer metastasis to the brain in a murine model. ( Amico-Ruvio, SA; Brown, EB; Dickerson, IM; Kelly, EA; Majewska, AK; Shapovalov, Y; Sipe, GO; Spielman, SC; Zettel, M, 2014) |
| "In C6 glioma cells, we studied acute administration of SSRI antidepressants - fluoxetine, sertraline and citalopram." | 3.78 | Effect of fluoxetine and adenosine receptor NECA agonist on G alpha q/11 protein of C6 glioma cells. ( Kováru, F; Kovárů, H; Lisá, V, 2012) |
| "We studied the effect of acute administration of fluoxetine or NECA agonist of adenosine receptor (GPCR) on C6 glioma cells and natural killer (NK) cell line, innate immunity." | 3.77 | Effect of fluoxetine or adenosine receptor NECA agonist on G-proteins of C6 glioma cells or NK immunocytes. ( Fiserová, A; Kovaru, F; Kovárů, H; Lisá, V; Ondráčkova, P, 2011) |
| "The highly lethal brain cancer glioblastoma (GBM) poses a daunting challenge because the blood-brain barrier renders potentially druggable amplified or mutated oncoproteins relatively inaccessible." | 1.62 | Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug. ( Armando, AM; Bi, J; Cloughesy, TF; Cravatt, BF; Curtis, EJ; Furnari, FB; Gimple, RC; Gu, Y; Jing, H; Khan, A; Koga, T; Kornblum, HI; Miki, S; Mischel, PS; Prager, B; Quehenberger, O; Reed, A; Rich, JN; Rzhetsky, A; Tang, J; Wainwright, DA; Wong, IT; Wu, S; Yang, H; Zhang, W, 2021) |
| "Management and resolution of the hydrocephalus was temporally associated with an improvement in his OCD compulsion symptoms." | 1.43 | Pediatric Obsessive-Compulsive Disorder Exacerbation and Obstructive Hydrocephalus: A Case Report. ( Bleakley, C; Leung, A; Loh, A; Saran, K; Stewart, SE, 2016) |
| "Temozolomide (TMZ) is a cytotoxic agent of the imidazotetrazine class, chemically related to dacarbazine." | 1.35 | Tuberculosis in a patient on temozolomide: a case report. ( de Barros e Silva, MJ; de Paiva, TF; Fanelli, MF; Gimenes, DL; Rinck, JA, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 10 (76.92) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Bi, J | 1 |
| Khan, A | 1 |
| Tang, J | 1 |
| Armando, AM | 1 |
| Wu, S | 1 |
| Zhang, W | 1 |
| Gimple, RC | 1 |
| Reed, A | 1 |
| Jing, H | 1 |
| Koga, T | 1 |
| Wong, IT | 1 |
| Gu, Y | 1 |
| Miki, S | 1 |
| Yang, H | 1 |
| Prager, B | 1 |
| Curtis, EJ | 1 |
| Wainwright, DA | 1 |
| Furnari, FB | 1 |
| Rich, JN | 1 |
| Cloughesy, TF | 1 |
| Kornblum, HI | 1 |
| Quehenberger, O | 1 |
| Rzhetsky, A | 1 |
| Cravatt, BF | 1 |
| Mischel, PS | 1 |
| Radin, DP | 1 |
| Purcell, R | 1 |
| Lippa, AS | 1 |
| Narasimha, VL | 1 |
| Basavaraju, R | 1 |
| Mangalore, S | 1 |
| Mehta, UM | 1 |
| Shapovalov, Y | 1 |
| Zettel, M | 1 |
| Spielman, SC | 1 |
| Amico-Ruvio, SA | 1 |
| Kelly, EA | 1 |
| Sipe, GO | 1 |
| Dickerson, IM | 1 |
| Majewska, AK | 1 |
| Brown, EB | 1 |
| Liu, KH | 1 |
| Yang, ST | 1 |
| Lin, YK | 1 |
| Lin, JW | 1 |
| Lee, YH | 1 |
| Wang, JY | 1 |
| Hu, CJ | 1 |
| Lin, EY | 1 |
| Chen, SM | 1 |
| Then, CK | 1 |
| Shen, SC | 1 |
| Ma, J | 1 |
| Yang, YR | 1 |
| Chen, W | 1 |
| Chen, MH | 1 |
| Wang, H | 1 |
| Wang, XD | 1 |
| Sun, LL | 1 |
| Wang, FZ | 1 |
| Wang, DC | 1 |
| Bielecka, AM | 1 |
| Obuchowicz, E | 1 |
| Leung, A | 1 |
| Bleakley, C | 1 |
| Loh, A | 1 |
| Saran, K | 1 |
| Stewart, SE | 1 |
| de Paiva, TF | 1 |
| de Barros e Silva, MJ | 1 |
| Rinck, JA | 1 |
| Fanelli, MF | 1 |
| Gimenes, DL | 1 |
| Kovárů, H | 2 |
| Kovaru, F | 2 |
| Ondráčkova, P | 1 |
| Lisá, V | 2 |
| Fiserová, A | 1 |
| Komlósi, G | 1 |
| Molnár, G | 1 |
| Rózsa, M | 1 |
| Oláh, S | 1 |
| Barzó, P | 1 |
| Tamás, G | 1 |
| Sokol, MS | 1 |
| Fujimoto, CK | 1 |
| Jackson, TK | 1 |
| Silberberg, PJ | 1 |
13 other studies available for fluoxetine and Brain Neoplasms
| Article | Year |
|---|---|
Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; | 2021 |
Oncolytic Properties of Ampakines
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Fluoxetine; Glioblastoma; H | 2018 |
Precuneus and psychiatric manifestations: Novel neurobiological formulations through lesion based connectivity mapping of psychopathology.
Topics: Anticonvulsants; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Brain Mapping; Brai | 2019 |
Fluoxetine modulates breast cancer metastasis to the brain in a murine model.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Proliferatio | 2014 |
Fluoxetine, an antidepressant, suppresses glioblastoma by evoking AMPAR-mediated calcium-dependent apoptosis.
Topics: Animals; Antidepressive Agents, Second-Generation; Apoptosis; Brain Neoplasms; Calcium; Cell Surviva | 2015 |
Fluoxetine synergizes with temozolomide to induce the CHOP-dependent endoplasmic reticulum stress-related apoptosis pathway in glioma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Prolif | 2016 |
Antidepressant drugs can modify cytotoxic action of temozolomide.
Topics: Antidepressive Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Division; | 2017 |
Pediatric Obsessive-Compulsive Disorder Exacerbation and Obstructive Hydrocephalus: A Case Report.
Topics: Brain Neoplasms; Child; Fluoxetine; Glioma; Humans; Hydrocephalus; Male; Obsessive-Compulsive Disord | 2016 |
Tuberculosis in a patient on temozolomide: a case report.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antibiotics, Antitubercular; Ant | 2009 |
Effect of fluoxetine or adenosine receptor NECA agonist on G-proteins of C6 glioma cells or NK immunocytes.
Topics: Adenosine-5'-(N-ethylcarboxamide); Animals; Antidepressive Agents, Tricyclic; Brain Neoplasms; Cell | 2011 |
Fluoxetine (prozac) and serotonin act on excitatory synaptic transmission to suppress single layer 2/3 pyramidal neuron-triggered cell assemblies in the human prefrontal cortex.
Topics: Adult; Aged; Brain Neoplasms; Excitatory Amino Acids; Excitatory Postsynaptic Potentials; Female; Fl | 2012 |
Effect of fluoxetine and adenosine receptor NECA agonist on G alpha q/11 protein of C6 glioma cells.
Topics: Adenosine-5'-(N-ethylcarboxamide); Animals; Brain Neoplasms; Cell Line, Tumor; Citalopram; Depressio | 2012 |
Anorexia nervosa and brain tumor in a 14-year-old girl.
Topics: Adolescent; Anorexia Nervosa; Brain Neoplasms; Depression; Female; Fluoxetine; Humans; Magnetic Reso | 2006 |